Clin Case Rep Int | Volume 7, Issue 1 | Review Article | Open Access
College of Agriculture and Bioresources, University of Saskatchewan, Canada
*Correspondance to: Gor Darshil SunilFulltext PDF
The clinical syndrome of Coronavirus Disease of 2019 (COVID-19) is caused by SARS (Severe Acute Respiratory Syndrome) is the etiology of this condition, which uses angiotensin-converting enzyme 2 to enter the cells. While the virus predominantly affects the respiratory system, it can also induce a number of severe cardiac instances, such as myocarditis, heart failure, acute coronary syndrome. COVID-19 treatment is more likely to succeed with Remdesivir and convalescent blood products, based on early findings from clinical trials, the National Institutes of Health (NIH), and the Food and Drug Administration (FDA) recommendations. Umifenovir, hydroxychloroquine and chloroquine, favipiravir, colchicine are additional possible treatments. As a result, all of these medications are undergoing further research. Furthermore, before administering the suggested medications, drugdrug interactions and safety risks must be considered. The development of innovative therapeutics for COVID-19 is a top goal. Because SARS-CoV-2 has such a devastating effect, delaying the spread of infections will benefit the health-care system, particularly in terms of the number of Intensive Care Unit visits (ICU). Several clinical studies are now underway all around the world.
Coronavirus; ACE-2; NIH and FDA; ICU; Remdesivir
Sunil GD. Cardiovascular Disease Risk in COVID-19 Patients: A Review. Clin Case Rep Int. 2023; 7: 1484.